Best News Network

Teva concludes US nationwide opioid settlement

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the conclusion of a full resolution on its US nationwide settlement agreement on opioid claims brought by US states, their subdivisions, and special districts, by reaching a separate settlement with the final state of Nevada. Teva will pay Nevada $193 million over 20 years (including all fees and costs), and this settlement resolves the case prior to trial, which had been scheduled to begin in August 2023.







Teva has resolved its opioid litigation with all 50 US states and more than 99% of the litigating subdivisions and special districts. The company anticipates making its first payment under the nationwide opioids settlement agreement in the second half of 2023. Teva has already begun shipments of its generic version of the life-saving medication, Narcan (naloxone hydrochloride nasal spray) under its prior opioid settlements, and will expand these shipments under the nationwide opioids settlement agreement in 2024.

While the final agreement includes no admission of wrongdoing by Teva, it remains in the company’s best interest, and in the interest of those impacted by the opioid crisis.

Teva’s share price is up 2.17% on Wall Street today, giving a market cap of $8.578 billion.

Published by Globes, Israel business news – en.globes.co.il – on June 8, 2023.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2023.


Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Business News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.